Mitoguazone

Drug Profile

Mitoguazone

Alternative Names: Methyl-G; Methyl-GAG; MGBG; Mitoguazone dihydrochloride; NSC 32946; Zyrkamine

Latest Information Update: 13 Nov 1998

Price : $50

At a glance

  • Originator Cancer Therapy and Research Center
  • Class Antineoplastics; Guanidines
  • Mechanism of Action Adenosylmethionine decarboxylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Non-Hodgkin's lymphoma; Non-small cell lung cancer; Pancreatic cancer; Prostate cancer

Most Recent Events

  • 13 Nov 1998 Discontinued-preregistration for Non-Hodgkin's lymphoma in USA (IV)
  • 13 Nov 1998 Discontinued-Clinical for Prostate cancer in USA (IV)
  • 13 Nov 1998 Discontinued-II for Non-small cell lung cancer in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top